Phase 3Recruiting
Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
Sponsored by University of Pennsylvania
About this study
The trial is an open-label randomized study that will examine whether switching to a selective IL23 inhibitor (guselkumab) is more effective than switching to a second TNFi (golimumab) among patients with PsA who have an inadequate response to a TNFi.
Enrolling at this location
New York University
New York, New York
I'm interestedThis study also enrolls at 13 other locations. See all.
Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.
Trial data sourced from ClinicalTrials.gov.